{"SPADE_UN_18884": {"Clinical Information": [], "Patent Information": [], "Sequence Information": {"SPADE ID": "SPADE_UN_18884", "Peptide Name": "SE-33 (reversed FF-33, synthetic AMPs, UCLL1)", "Source": "sequence reversal, sequence shuffling, designed, man-made sequences", "Family": "Not found", "Gene": "Not found", "Sequence": "SETRPVLNRLFDKIRQVIRKFEKGIKEKSKRFF", "Sequence Length": 33, "UniProt Entry": "Ref", "Protein Existence": "Not found", "Biological Activity": ["Anti-Gram+", "Anti-Gram-"], "Target Organism": "Not found", "Hemolytic Activity": "Not found", "Cytotoxicity": "Not found", "Binding Target": "Not found", "Linear/Cyclic": "Not found", "N-terminal Modification": "Not found", "C-terminal Modification": "Not found", "Stereochemistry": "Not found", "Structure Description": "Not found", "Formula": "Not found", "Mass": 4094.81, "PI": 11.04, "Hydrophobicity": -0.92, "Half Life": "Not found", "Function": "Not found", "Literature": [{"Author": "Trenin AS, Arzumanian VG, Zhmak MN, Shelukhina IV, Makarova YV, Ivanov IA, Bychkova OP, Budikhina AS, Balyasova LS, Tsetlin VI. 2019", "Reference": "Russian J Bioorg Chem 2019 June 5;45:89-100.Publisher", "Title": "Synthesis and Antimicrobial Activity of a New Drug Based on a Retro-Analog of Cathelicidinâ€”Polypeptide SE-33"}], "Frequent Amino Acids": "KRF", "Absent Amino Acids": "ACHMOUWY", "Basic Residues": 11, "Acidic Residues": 4, "Hydrophobic Residues": 12, "Polar Residues": 18, "Positive Residues": 11, "Negative Residues": 4, "Net Charge": 7, "Comments": "Sequence analysis: APD analysis reveals that this sequence is most similar (39.39%) toRetro-FK-13Activity: active against E. coli (MIC 15-20 ug/ml), S. aureus (MIC 15 ug/ml), and L. casei (MIC 20 ug/ml) (Gasanov et al., 2024). Also: C.albicans 927 (MIC 1024 ug/ml), C. neoformans 3465 (MIC 62.5 ug/ml),  R. mucilaginosa 132 (MIC 62.5 ug/ml), T. cutaneum no. 18 (MIC 31.2 ug/ml), Geotrichum sp. 1206 (MIC 31.2 ug/ml).Structure:  it is more helical in 50% TFE.Animal model:mouse: MRSA infected animals treated with Wharton's Jelly-Derived MSCs (WJ-MSCs) engineered to express the antimicrobial peptide SE-33 showed safety and efficacy in reducing bacterial load, inflammation, and mortality in an S. aureus pneumonia model.Recombinant production:stem cells: SE-33 expressing cells are used for treatment (Gasanov et al. 2025).Updated 3/2025", "Similar Sequences": [{"SPADE_ID": "SPADE_UN_18885", "Similarity": 1.0, "Sequence": "SETRPVLNRLFRLFDKIRQVIRQVIRKFEKGIKEKSKRFFEGRGSLLTCGDVEENPGP"}, {"SPADE_ID": "SPADE_UN_01706", "Similarity": 1.0, "Sequence": "RLFDKIRQVIRKF"}, {"SPADE_ID": "SPADE_UN_18940", "Similarity": 1.0, "Sequence": "RLFDKIRQVIRK"}]}}}